Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the efficacy findings of the phase 2 CRESTONE trial (NCT04383210) in patients with 

 fusion–positive, advanced solid tumors.

The phase 2, open-label, international trial evaluated seribantumab in patients with recurrent, locally advanced and/or metastatic solid tumors that harbor 

Data presented at the 2022 Annual ASCO Meeting showed seribantumab displayed both good efficacy and safety, Carrizosa says. As of April 2022, the investigator-assessed overall response rate (ORR) was 33% with a disease control rate of 92% among 12 evaluable patients, Carrizosa explains. Notably, most patients enrolled with 

 fusion–positive non–small cell lung cancer, and this subgroup achieved an ORR of 36%, Carrizosa adds.

Among all patients, there were 2 partial responses and 2 complete responses, leading to promise that seribantumab produced antitumor activity in patients with 

Videos

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.


Daniel Carrizosa, MD, MS

Articles

Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors